Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Health Care

Health Care

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Movers
  • News
  • Penny Stocks
  • Trading Ideas

Dry Eye Disease Affects Around 50M Americans, OKYO Pharma’s Candidate Shows Safety In Mid-Stage Study

By Vandana Singh
October 5, 10:27 AM
OKYO Pharma Limited (NASDAQ: OKYO) announced that its first drug candidate, OK-101, presently in a 240-patient phase 2 trial in patients with dry eye disease (DED) is currently showing a positive safety profile in 

OKYO

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • News
  • Small Cap

Gene Therapy Player UniQure To Lay Off 20% Of Workforce, Stop Parkinson’s Study

By Vandana Singh
October 5, 10:23 AM
uniQure N.V. (NASDAQ: QURE) announced to cut about 20% of its total workforce, or about 114 jobs, and end investments in more than half of its research and technology 

QURE

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • News

Merck’s Best Selling Cancer Drug Meets One Goal In Late-Stage Bladder Cancer Study

By Vandana Singh
October 5, 9:35 AM
Merck & Co Inc (NYSE: MRK) announced that the Phase 3 AMBASSADOR (A031501) trial (KEYNOTE-123) evaluating Keytruda met one of its dual primary endpoints of disease-free survival for the adjuvant treatment of localized muscle-invasive urothelial carcinoma and 

ALPMF

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Movers
  • News
  • Penny Stocks

Longeveron’s Alzheimer’s Candidate Meets Safety Goal In Mid-Stage Study

By Vandana Singh
October 5, 9:33 AM
Longeveron Inc (NASDAQ: LGVN) announced topline results from the Phase 2a trial of its investigational product Lomecel-B for 

LGVN

Read More
2 minute read
  • FDA
  • General
  • Health Care
  • News

Lab-Developed Tests Under FDA Scrutiny: What It Means For Startups

By Vandana Singh
October 5, 9:06 AM
A proposed regulatory shift has injected uncertainty into the laboratory-testing market just as startups advance various tests to detect diseases sooner and personalize treatments.

AGNG

Read More
2 minute read
  • Biotech
  • General
  • Government
  • Health Care
  • Large Cap
  • Markets
  • News

Novo Nordisk’s Wegovy Success Uplifts Denmark’s Economy And Reputation, But With Caution

By Vandana Singh
October 5, 9:01 AM
Novo Nordisk A/S's (NYSE: NVO) remarkable success with its weight-loss treatment, Wegovy, is not only a cause for celebration but also a source of 

LVMHF

Read More
1 minute read
  • Biotech
  • General
  • Government
  • Health Care
  • Large Cap
  • News

No Merck’s COVID-19 Pill – US Government Ceases Free Distribution

By Vandana Singh
October 5, 8:59 AM
The U.S. government is set to cease the distribution of free doses of Merck & Co Inc's (NYSE: MRK) COVID-19 antiviral treatment Lagevrio (molnupiravir), by mid-November, shifting its availability to the commercial market. 

MRK

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • Movers
  • News
  • Penny Stocks

Regulatory Hurdle For Innate Pharma’s Blood Cancer Studies

By Vandana Singh
October 5, 8:19 AM
The FDA has placed a clinical hold on Innate Pharma SA's (NASDAQ: IPHA) lacutamab Investigational New Drug (IND), leading to a pause in new patient enrollment in ongoing lacutamab trials IPH4102-201 (Phase 2 TELLOMAK) and 102 (Phase 1b PTCL). 

IPHA

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Media
  • News

Walmart Reports ‘Slight Pullback’ In Food Demand As ‘Miracle’ Weight-Loss Drug Ozempic Gains Popularity

By Benzinga Neuro
October 5, 2:04 AM
Walmart Inc. (NYSE:WMT) indicates that there has been a decrease in shopping demand due to the use of appetite-suppressing…

NVO

Read More
1 minute read
  • Analyst Color
  • Analyst Ratings
  • Biotech
  • FDA
  • General
  • Health Care
  • Movers
  • News
  • Small Cap
  • Trading Ideas

Novavax’s COVID-19 Shot Just In Time, Optimism Surrounds As Demand Picks Up Momentum

By Vandana Singh
October 4, 3:19 PM
Tuesday, the FDA granted an emergency use nod to Novavax Inc's (NASDAQ: NVAX) COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) (NVX-CoV2601) for active immunization to prevent COVID-19 in 

NVAX

Posts pagination

Previous 1 … 147 148 149 … 478 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service